Scalper1 News
The market is still in a correction, which means that it’s not the best time to buy; but it never hurts to keep an eye on some top performers, such as these hot drugmakers on the IBD 50. Valeant Pharmaceuticals (VRX) said at the start of the month that it will shell out $445 million in a psoriasis drug licensing deal with AstraZeneca (AZN). The drug candidate, brodalumab, may be effective, but AstraZeneca’s old partner Amgen (AMGN) nixed the Scalper1 News
Scalper1 News